Berstein G, Zhang Y, Berger Z, et al. - Given that interleukin (IL)‐17A and IL‐17F expression is mediated by transcription factor retinoic acid‐related orphan receptor 2 (RORC2, also referred to as RORγT) and that there exists a central role of IL‐17A in the pathogenesis of several inflammatory disorders, including psoriasis, researchers tested PF‐06763809 (a topical RORC2 inverse agonist that potently inhibits IL‐17A generation in preclinical assays) with respect to its safety, tolerability and impact on skin infiltrate thickness among patients suffering from mild/moderate chronic plaque psoriasis in this randomized, double‐blind, first‐in‐human study. Each of the following six treatments was received by patients once daily for 18 days: three topical doses (2.3%, 0.8%, 0.23%) of PF‐06763809, a vehicle and two active comparators (betamethasone and calcipotriol). At the end of the study, there were 17 participants. In this study, the good tolerability as well as an acceptable safety profile of PF‐06763809 was observed, using a psoriasis plaque test design, in patients with psoriasis, however, there occurred no decrease in skin infiltrate thickness or disease biomarkers.